Clinical Edge Journal Scan

Palbociclib+ET fails to prolong PFS in AI-resistant metastatic breast cancer


 

Key clinical point: Palbociclib+endocrine therapy (ET) did not yield superior progression-free survival (PFS) vs. capecitabine in patients with aromatase inhibitor-resistant metastatic breast cancer (AIR-MBC) but was well tolerated and improved quality of life (QoL).

Major finding: Median PFS with palbociclib+fulvestrant vs. capecitabine was 7.5 vs. 10.0 months (adjusted hazard ratio [aHR], 1.13; P = .398). Palbociclib+ET did not show PFS superiority vs. capecitabine in patients with wild-type estrogen receptor-1 AIR-MBC (8.0 vs. 10.6 months; aHR, 1.11; P = .404). Palbociclib+ET was better tolerated and improved QoL (aHR, 0.67; P = .001).

Study details : Phase 3 PEARL trial randomly allocated postmenopausal women with AIR-MBC to receive either palbociclib+exemestane or capecitabine (n=296) or palbociclib+fulvestrant or capecitabine (n=305).

Disclosures: This study was supported by Pfizer and AstraZeneca and sponsored by GEICAM Spanish Breast Cancer Group. The lead author reported ties with AstraZeneca, Pfizer, Amgen, Taiho Oncology, Roche/Genentech, Novartis, PharmaMar, Eli Lilly, PUMA, and Daiichi-Sankyo. Other investigators reported owning stocks, being an employee, receiving support, and/or consulting for various pharmaceutical companies including Pfizer and AstraZeneca.

Source: Martin M et al. Ann Oncol. 2020 Dec 29. doi: 10.1016/j.annonc.2020.12.013 .

Recommended Reading

First mammography guidelines for older breast cancer survivors
MDedge Hematology and Oncology
Model predicts acute kidney injury in cancer patients a month in advance
MDedge Hematology and Oncology
COVID-19 vaccination in cancer patients: NCCN outlines priorities
MDedge Hematology and Oncology
Obesity ‘clearly’ not tied to worse survival in metastatic breast cancer
MDedge Hematology and Oncology
Findings could change breast cancer risk management
MDedge Hematology and Oncology
Aspirin linked to reduced bladder, breast cancer mortality
MDedge Hematology and Oncology
Study flags cardiovascular disease in men with breast cancer
MDedge Hematology and Oncology
Clinical Edge Commentary: Breast Cancer February 2021
MDedge Hematology and Oncology
Partial breast irradiation vs. whole breast irradiation for early breast cancer
MDedge Hematology and Oncology
One-third of HER2+ and triple-negative metastatic breast cancer patients develop brain metastases
MDedge Hematology and Oncology